Rising Prevalence Of Venous Diseases Fuels Market Growth Is Supporting Development Across The VELETRI Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The VELETRI Market?

The veletri market size has shown substantial growth in recent years. It is projected to expand from $1.45 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This historical expansion can be attributed to factors such as the clinical efficacy of epoprostenol, an increase in the diagnosis of pah, hospitals’ reliance on iv prostacyclins, limited availability of oral alternatives, and improved pah survival rates.

The veletri market is projected to experience robust growth over the coming years, reaching a valuation of $2.07 billion by 2030, with a compound annual growth rate (CAGR) of 7.4%. This anticipated expansion during the forecast period is attributed to factors such as an increase in pah prevalence, the development of specialty pah centers, a heightened demand for stable formulations, wider adoption of infusion therapy, and greater awareness of pah. Significant trends expected in this period include the increasing embrace of non-refrigerated prostacyclin therapies, a rise in the use of continuous infusion pah treatments, growing demand for advanced pah vasodilators, the expansion of hospital-based pah management, and an increased focus on enhancing pah patient mobility.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21314&type=smp

Which Significant Factors Are Encouraging Growth In The VELETRI Market?

The growing incidence of venous diseases is anticipated to propel the expansion of the VELETRI market in the future. Venous diseases are characterized by impaired blood flow in the veins, resulting in swelling, pain, and potential complications like varicose veins and deep vein thrombosis. The heightened occurrence of these conditions is fueled by factors such as an aging demographic, sedentary habits, obesity, and advancements in diagnostic capabilities. VELETRI is utilized to enhance exercise capacity and diminish symptoms in patients with venous diseases that affect the pulmonary vasculature. For instance, in January 2025, information from the Centers for Disease Control and Prevention, a US-based governmental organization, indicated that up to 900,000 individuals in the United States are annually impacted by venous thromboembolism (VTE), a condition marked by blood clots, with an estimated 60,000 to 100,000 fatalities attributed to VTE each year. Therefore, the increasing prevalence of venous diseases is a significant factor driving the growth of the VELETRI market.

How Is Segment Classification Applied In The VELETRI Market?

The veletri market covered in this report is segmented –

1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation

2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution

2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution

What Trends Are Affecting The Growth Of The VELETRI Market?

Key companies operating within the Veletri market are focused on broadening access through generic formulations, such as the FDA-approved epoprostenol sodium injection, to provide economical treatment solutions for patients suffering from pulmonary arterial hypertension. Generic Veletri refers to versions of the branded epoprostenol product that are therapeutically equivalent, fulfilling FDA requirements for quality, safety, and efficacy, and delivering the same clinical benefits at a lower cost. As an illustration, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical entity, obtained FDA approval for its generic Veletri (epoprostenol sodium) injection. This product is supplied in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and exhibits the identical prostacyclin mimetic activity as its branded counterpart, assisting in improving exercise tolerance and managing symptoms in PAH patients.

Who Are The Key Market Participants In The VELETRI Market?

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

Access The Complete VELETRI Market Report:

https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

Which Region Is The Primary Market For The VELETRI Market?

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access VELETRI Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=21314&type=smp

Browse Through More Reports Similar to the Global VELETRI Market 2026, By The Business Research Company

Vermiculite Market Report 2026

https://www.thebusinessresearchcompany.com/report/vermiculite-global-market-report

Vanadium Market Report 2026

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Gelatin Market Report 2026

https://www.thebusinessresearchcompany.com/report/gelatin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795